Nolvadex is a dietary supplement that was developed originally as an over the counter male enhancement pill. The manufacturer of Nolvadex is KEG Pharmaceuticals and the product was marketed under the names Extenze, Rolo, Vivaxa and Levitra. The brand name was discontinued in the U.S., however, if generic versions of the product were approved by the FDA. The FDA will not approve any drug that contains a prescription or controlled substance as an over the counter medication.
One of the side effects associated with taking Nolvadex was sexual dysfunction. Some patients reported experiencing erectile dysfunction including frequency, strength, and duration of erection, difficulty maintaining an erection, and difficulty starting and maintaining a steady erection. Other patients experienced hot Nolvadex flashes and vaginal dryness, but did not report any adverse effects on their cardiovascular health. There are several medications available to treat erection problems including Viagra, Cialis, and Levitra. These medications all use similar chemical formulations and the difference between them lies mainly in the ingredients used to produce the drug.
One of the most common adverse events associated with Nolvadex was breast cancer. It was reported that one of the thousands of women who took Nolvadex had breast cancer and three of those women died as a result. Nolvadex did not cause breast cancer according to the reports from the clinical trials. However, two of the women who took the female enhancement pill had benign breast cancer and one woman had prostatic intraepithelial neoplasia (PIDS). It was not known if these patients actually had breast cancer or if the adverse reaction was a side effect of the Nolvadex.
One of the more serious events associated with Nolvadex was the development of rashes, blisters, itching and nausea. Many of the women who took nolvadex became extremely allergic to the chemical compounds used in the manufacturing of the supplement. Women began experiencing these symptoms within five to eight weeks of beginning the therapy and sometimes these outbreaks lasted for longer.
After considering the various risks associated with the use of Nolvadex plus the results from the studies, the Food and Drug Administration (FDA) concluded that there was no significant evidence that Nolvadex was unsafe. According to the FDA the majority of women who experienced the adverse effects of nolvadex had an allergy to tamoxifen citrate. Tamoxifen is an anti-estrogen that acts to reduce breast cancer and its risks have been considered by the FDA to be a possible link to the development of breast cancer in women. The agency was unable to conclude that the use of nolvadex plus tamoxifen citrate resulted in increased risk for breast cancer. Since most women do not suffer from a current or previous history of breast cancer, the FDA recommended that all females taking tamoxifen be carefully monitored for breast cancer.
While the FDA has not acknowledged a link between Nolvadex and breast cancer, many physicians believe that the combination of nolvadex plus estrogen may lead to an increased risk for certain types of cancer. Nolvadex itself has not been identified as a cause of cancer in breast feeding women, but since women who are breast-feeding may already be at a higher risk for certain types of cancer, it is possible that using the medication may affect their chances of developing these conditions. Nolvadex can cause a woman’s body to retain more water, which may affect fluid retention and bloating of the abdomen. The medication may also cause changes in levels of cervical fluid. These changes may affect the effectiveness of contraceptives during pregnancy.